COMP <GO>
CORT vs UNH // EV/EBITDA & P/E VALUATION
Corcept Therapeutics Incorporated (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CORT 7
— UNH 7
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $85.95 (-0.38%) • MKT CAP: $9.29B
valuation
95.0x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.57% | +7.43 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 11.47% | -6.67 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 16.4x | +78.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 6.48% | -4.95 | UNH | /fcf-yield <GO> |
| Operating Margin | 5.90% | 4.82% | +1.08 | CORT | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 3.14% | +9.96 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 6.46% | +6.34 | CORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 59.2 | -28.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | CORT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 17.1x | +61.21 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.29B | $368.83B | -$359.54B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | UNH REV | CORT GROSS % | UNH GROSS % | CORT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $447.57B | 98.3% | 88.7% | $141.8M | $16.07B |
| FY 2024 | $675.0M | $400.28B | 98.4% | 88.3% | $196.1M | $20.70B |
| FY 2023 | $482.4M | $371.62B | — | 89.6% | $105.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
UNH // BETA 0.33